It is true Gary that the company has, as of now, enough
It is true Gary that the company has, as of now, enough money to fund their ongoing studies until March 31, 2020. This is the good news. However, the 10-K also points to some potential financial potholes that the company may have to get past. It should be no surprise that they have to do with Discovery.
Here are two scenarios:
1. Right now there are still 440 Preferred Shares that have yet to be redeemed. @ $10,000 each this equals $4.4 Mil. As of Dec. 31, 2018 the company was not in compliance with the Equity Conditions (read... Dr, Baruch assault charge = "triggering" event) therefore Discovery has the unilateral right to request redemption in cash at the rate of 1/12 per month after 270 days (not sure if the redemption is 1/12 of the original 500 shares or the remaining 440 shares). If it's the latter, that equals to 36.66 shares = $366K per month. In other words the company would quickly run out of money before the end of the year.
2. The other possibility is that Discovery may just keep on converting their remaining preferred shares to VERY CHEAP common shares. Think about this for a moment. Between the beginning of the year to the date of the issuance of the current financial statements, Discovery converted 50 Preferred shares ($500K) and in return they were issued 24,871,345 common shares. This works out to an average of about $.02/share!! The next conversion could be at a much lower average price. Even at an average of $.02, $4.4 Mil would require issuance of an additional 220 Million more shares. Add this to the current outstanding shares and all of a sudden we are perilously close to the 500 million authorized shares.
Both of the above scenarios spell the need for some sort of influx of money. Obviously the sooner they do it the better. In a way I agree with you that if the idea of a R/S was abandoned it would't be long before the S/P went up again. The company could then sell the higher valued shares to raise the needed funds. If the company sits on its heels, and Discovery converts its preferred shares, we would get to a situation where the shares required reaches the maximum authorized limit of 500 million shares. Then What? The company would have no choice but to implement a R/S just so they can continue with their work.
All of the above points to the need for the company to act swiftly to mitigate the damage. My hope is that they already have a financial plan in place, one that they will soon be announcing.
2
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...
Continue Reading
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...
Continue Reading
Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....
Continue Reading
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...
Continue Reading
Top 5 Most Recently Viewed Articles
States Vulnerable to Economic Downturns The landscape of economic stability is shifting, and many residents might be unaware of how their home states rank in terms of recession preparedness. Recent analyses reveal striking differences in resilience that could significantly impact everyday Americans. With numerous warnings about incoming economic turbulence, it’s crucial...
Continue Reading
Liquidia Corporation Announces Significant Funding Boost Liquidia Corporation (NASDAQ: LQDA), a prominent biopharmaceutical company, is thrilled to announce that it has secured an additional $50 million to support the launch of its innovative treatment, YUTREPIA™. This exciting development follows a pivotal legal victory where a U.S. District Court ruled against a...
Continue Reading
Paratus Energy Services Ltd. Reports Mandatory Trade Notification Paratus Energy Services Ltd. has recently announced a significant trade notification involving a close associate of one of its board members. The company, which operates in the energy sector, has revealed that a fund managed by Lodbrok Capital LLP has completed a trade involving its shares. This information...
Continue Reading
Angel's Global Release of David Musical Animated musical builds powerful momentum as early domestic pre-sales surge close to $6 million Angel (NYSE: ANGX), a leading media and technology company championing values-driven stories, is setting the stage for the theatrical release of the eagerly awaited animated musical David across 43 international markets. This significant...
Continue Reading
LifeMD, Inc. Announces Quarterly Dividend LifeMD, Inc. (NASDAQ: LFMD), recognized for its pioneering virtual primary care offerings, has announced an important cash dividend for its shareholders. The Company's Board of Directors has declared a cash dividend of $0.5546875 per share on the 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ: LFMDP). This...
Continue Reading